Diabetes Dialogue: SURMOUNT-2 Reaction, Omnipod GO, and Verapamil for T1D
May 03, 2023, 01:24 PM
Share
Subscribe
In this episode, hosts offer their reaction to topline data from the SURMOUNT-2 trial examining tirzepatide for weight management in T2D, the FDA's clearance of the Omnipod GO device, and results of the CLVer trial.